Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps an Outperform rating on the ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Canaccord lowered the firm’s price target on Sage Therapeutics (SAGE) to $8 from $9 and keeps a Hold rating on the shares. The firm said they ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We ...

Analysts expect the Cambridge, Massachusetts-based company to report quarterly earnings at $3.36 per share, up from $2.95 per ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...